Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the transaction, the chief executive officer owned 362,152 shares in the company, valued at approximately $10,133,012.96. This represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Friday, July 10th, Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.42, for a total value of $284,200.00.

Bicara Therapeutics Price Performance

BCAX traded up $0.87 during trading on Wednesday, reaching $24.63. 810,259 shares of the stock traded hands, compared to its average volume of 608,476. The stock’s 50-day simple moving average is $25.90 and its two-hundred day simple moving average is $21.69. Bicara Therapeutics Inc. has a fifty-two week low of $10.30 and a fifty-two week high of $30.99. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -8.86 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting the consensus estimate of ($0.82). Research analysts anticipate that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current fiscal year.

More Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported a second-quarter loss of $0.82 per share, described as narrower than expected and matching the cited analyst consensus. The result helped support the view that the company is maintaining financial discipline while advancing its pipeline. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: The company said enrollment in its pivotal cancer study is progressing and remains on track for completion in 2026. Wedbush viewed the enrollment timeline as a positive catalyst for BCAX’s clinical program. Bicara Therapeutics’ Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on expectations for Bicara’s clinical and commercial prospects. Benzinga
• Positive Sentiment: Recent commentary remains constructive despite broader market headwinds, with optimism centered on the company’s pipeline progress and upcoming clinical milestones. Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
• Neutral Sentiment: Bicara also announced strategic leadership transitions intended to support its next phase of execution and growth. The changes may improve operational focus, but they introduce an element of transition risk. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Wells Fargo raised its price target from $16 to $23 but retained an Equal Weight rating. Its target remains below the referenced trading level, signaling a more cautious view than BTIG’s forecast. Benzinga

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Bicara Therapeutics in the 2nd quarter worth approximately $114,250,000. Deutsche Bank AG acquired a new position in Bicara Therapeutics during the second quarter valued at approximately $4,276,000. SCS Capital Management LLC acquired a new position in Bicara Therapeutics during the second quarter valued at approximately $1,586,000. Bank of New York Mellon Corp bought a new position in shares of Bicara Therapeutics in the second quarter valued at approximately $3,583,000. Finally, Walleye Capital LLC bought a new position in shares of Bicara Therapeutics in the second quarter valued at approximately $10,487,000.

Analysts Set New Price Targets

BCAX has been the topic of a number of research reports. Mizuho increased their price objective on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. The Goldman Sachs Group boosted their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday. Guggenheim started coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 price target on the stock. Finally, Morgan Stanley raised their price target on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.73.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.